DARA Biosciences — Investor Presentation (February 2014)
29 slides from DARA Biosciences's investor presentation, Feb 10, 2014

Slide 1: DARA BioSciences Investor Presentation February 2014
DARA BiCSciences Investor Presentation February 2014

Slide 2: Forward Looking Statements
Forward Looking Statements BARA BiOSciences All totements in this presentation that are not historical are forward-looking statements within the meaning of the Securities Exchange Act of 1934, as amended, and are subject to risks and uncertainties. These statements are based on the Current expectati

Slide 3: Corporate Overview
Corporate Overview Product Portfolio Management Team Product Strategy

Slide 4: Corporate Overview
Corporate Overview DARA BOS: DARA Biosciences, Inc. is a specialty pharmaceutical company focused on the commercialization of oncology treatment and supportive care pharmaceutical products "Market capitalization: $21.7 million (as of January 29, 2014) | NASDAQ:DARA Headquarters in Raleigh, NC ‘Natio

Slide 5: Oncology Supportive Care
Oncology Supportive Care DARA BOs What is oncology supportive care? “Care given to support the quality of life in cancer patients. The goal is to prevent or treat as early as possible the symptoms of the disease, side- effects caused by treatment and psychological, social and spiritual problems caus

Slide 6: Product Strategy - Oncology Supportive Care
Product Strategy - Oncology Supportive Care PARA SOScenc Why oncology supportive care? Large, Untapped & Growing Market significant Commercial Opportunity Unique Positioning Product Synergies Virtually all cancer treated patients involved Improved therapeutics increasing the demand for supportive ca

Slide 7: Product Portfolio
Product Portfolio BARA BiOSciences Hyaluronic acid oral rinse ge! ee Oral quid tamonfen crate breast concer | ==) | Pr oo ws | —————| ‘Mission Pharmacal_ A sore | burns & skin changes from radiation | Feral 90 ual ren delvery ‘enema supplement i inasto™ ‘Alenaronotesodum effervescent abl Mission Pha

Slide 8: Management Team
Management Team DARA BiO Science: DARA’ s management team is highly experienced with over 100 years of collective expertise in clinical development, operations, sales & marketing, strategic planning, and technical operations & manufacturing. ‘= Dr. David J. Drutz, MD ~ Chief Executive Officer & Chie

Slide 9: Product Strategy - Synergies
Product Strategy - Synergies BARA BiOSciences DARA can leverage its newly established portfolio of oncology supportive care products. *DARA' s product portfolio can treat an array of oncology related indications in the same patient. Breast Cancer Patient (illustrative) eo * oelelai aquoral Dry mouth

Slide 10: Product Detail
= Product Detail © Gelclair® © Soltamox®

Slide 11: Gelclair
Gelclair® DARA BiOScience Gelclair® is a patent protected, oral bioadherent gel (mouthwash) indicated for the management and relief of the painful symptoms of oral mucositis, a significant side effect for patients receiving chemotherapy or radiotherapy. e@sgelclair Indication + Oral mucositis/stomat

Slide 12: Gelclair - How to Use
Gelclair® - How to Use BARA BiOSciences HOW TO USE GELCLAIR Gelclair is simple, quick, and easy to administer 1,.POUR the entire contents of the singledose GELCLAIR® packet ino @ glass and coda 1 tablespoon of water (15 ml)* ‘S, 5.WAIT 2.sTR at least mixture well anc 30-60 minvies use immediately be

Slide 13: Gelclair - Mechanism of Action
Gelclair® - Mechanism of Action DARA BOs When applied via mouth rinse, Gelclair® forms a protective film over the oral mucosa creating a shield over the nerve endings protecting from over-stimulation (pain) for up to 5 to 7 hours. *This reduces pain and helps patients eat and drink more easily, both

Slide 14: Patients Regard Oral Mucositis As A Major Problem
Patients Regard Oral Mucositis As A Major Problem, Secondary Only to Chemotherapy Induced Nausea and Vomiting (CINV) DARA SiOSciences” Most Preferred Ranked Assessment of Chemotherapy Side Effects of Patients with Ovarian Cancer YS Obl gs we? Vike CL felines S cA State Sone etal faking nd sytem seen

Slide 15: Gelclair Performance 2013
Gelclair Performance 2013 DARA BiOScie Gelclair Total Boxes Sold By Quarter 2013 «», = @ oe ae Number of Boxes

Slide 16: Soltamox
Soltamox® DARA BiOSciences Soltamox? is the only patent protected, oral liquid formulation of tamoxifen in the U.S. and is an important option for breast cancer patients who have difficulty adhering to tablet therapy due to preference or need. a soltamoxe + Treatment of metastatic breast cancer + Ad

Slide 17: Soltamox Performance 2013
Soltamox Performance 2013 DARA BiOSc: Soltamox Total RX By Quarter 2013 (1) Esso | = ‘7 5 100 a a oa ae

Slide 18: Complementary Supportive Care Products
= Complementary Supportive Care Products * Sales Force

Slide 19: Complementary Supportive Care Portfolio
Complementary Supportive Care Portfolio para sidscences Complementary Supportive Care Product » . Bionect® . @ . Ferralet® 90 : e Binosto” : e . Aquaoral” = Patent protected cream / gel Topical application Unique patented blend of 2 different forms of iron Once daily Easy oral effervescent administr

Slide 20: Sales Force - Expansion
Sales Force - Expansion DARA BOs Recently expanded sales presence will drive revenue for its supportive care portfolio. "Increased reach and frequency on highest prescribing oncologists "Expansion to 20 national sales representatives (from 5) contracted with ALAMO Pharma Services (fully trained and

Slide 21: Sales Force - National Coverage
Sales Force — National Coverage DARA BiO Sciences

Slide 22: Development Stage Opportunity - KRN5500
= Development Stage Opportunity - KRNSSOO

Slide 23: KRN5500: A Novel Phase 2b Drug
KRN5500: A Novel Phase 2 Drug BARA BiOSciences DARA’ s | development compound targets painful CCIPN* "Area of significant unmet medical need ~Existing approved therapies are ineffective "Impressive Phase 2a clinical results Fast track” status from FDA | Seeking Orphan designation Why is KRNS500 so e

Slide 24: KRN5500 Phase 2a Primary Endpoint
KRN5500 Phase 2a Primary Endpoint DARA BIOs: KRN5500 reduces median target pain intensity 24%:placebo 0% (p=0.03) 2» Ew # s 0 Placebo ™ 2 +0 - . 2 © = x s % KRNS500 @ 5 S00 6 34 8 6 7 8 8 wt Endpoint Visit(weoks) = Primary Endpoint = median Clinic NRS scores 1 week after final dose = KRN5SSOO 24%; P

Slide 25: Capitalization Table, Anticipated Key Events, Investment Summary
* Capitalization Table * Anticipated Key Events * Investment Summary

Slide 26: Capitalization Table - Pre Split
Capitalization Table — Pre Split DARA BiOSciences “APITALIZATION TABLE as of February 3, 2014 ‘Common Shares Outstanding 31,073,850 Series B-2 Convertible Preferred Shares (Conversion Price $0.49) 102,041 Series B-4 Convertible Preferred Shares (Conversion Price $0.49) 104,082 Series A Convertible P

Slide 27: Anticipated Key Events
Anticipated Key Events BARA BiOSciences Multiple anticipated key events expected to continue to build momentum = Expanded national sales organization (Mission/ALAMO) ~ Q1 = Commercial rollout/execution — ongoing Potential KRNSSOO orphan designation — ongoing Seeking development partner for KRN5S5S00

Slide 28: Investment Summary
Investment Summary DARA BiOSciences Compelling Investment Opportunity | Nea! = Unique strategic positioning with a portfolio of synergistic oncology supportive care products = Limited pharma companies focused on supportive care = Expanded sales force with an experienced / successful CSO = Novel phas

Slide 29: DARA BioSciences Corporate Headquarters
DARA BiCSciences Corporate Headquarters: 8601 Six Forks Road, Suite 160 Raleigh, NC 27615 Office Contact: (919) 872-5578
Source: SEC EDGAR · 8-K filed Feb 10, 2014
More decks from DARA Biosciences Inc
Merger or Acquisition (June 2015)14 slides · Jun 5, 2015
Q3 2013 Earnings Presentation16 slides · Nov 14, 2013
Investor Presentation (October 2013)32 slides · Oct 29, 2013
IPO Roadshow (March 2012)25 slides · Mar 26, 2012
IPO Roadshow (October 2008)32 slides · Oct 29, 2008
IPO Roadshow (July 2008)29 slides · Jul 9, 2008